The studies are all phase I and II, plus a phase III study, which is evaluating the efficacy and safety profile of a MET inhibitor (sitravatinib) plus nivolumab in metastatic non-squamous LC patients who have previously experienced disease progression or after platinum-based chemotherapy and ICI-based therapy (NCT03906071, Supplementary Table S3). The gene discussed is MET; the disease is laryngotracheoesophageal cleft.